- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04596631
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PIONEER TEENS)
March 19, 2024 updated by: Novo Nordisk A/S
Efficacy and Safety of Oral Semaglutide Versus Placebo Both in Combination With Metformin and/or Basal Insulin in Children and Adolescents With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo).
Semaglutide will be tested to see how well it works compared to the dummy medicine.
The study will also test if semaglutide is safe in children and teenagers.
Participants will either get semaglutide or the dummy medicine - which one is decided by chance.
Participants will take 1 tablet of the study medicine every morning on an empty stomach.
They have to wait 30 minutes before they eat, drink or take any other medication by mouth.
The study will last for about 1 year and 3 months (66 weeks).
Participants will have 12 clinic visits and 8 phone calls with the study doctor.
At all 12 clinic visits, participants will have blood samples taken.
Participants will also be asked some questions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
132
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
New South Wales
-
Gosford, New South Wales, Australia, 2250
- Not yet recruiting
- Gosford Hospital
-
Westmead, New South Wales, Australia, 2145
- Not yet recruiting
- Westmead Children's Hospital- The Clinical Research Centre
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- Not yet recruiting
- Women's & Children's Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Children's Hospital
-
Parkville, Victoria, Australia, 3052
- Recruiting
- Murdoch Children'S Research Institute
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Recruiting
- Perth Children's' Hospital
-
-
-
-
-
Salzburg, Austria, 5020
- Recruiting
- Universitätsklinik für Kinder und Jugendheilkunde Haus E
-
-
-
-
-
Brussel, Belgium, 1090
- Withdrawn
- UZ Brussel
-
Bruxelles, Belgium, 1200
- Withdrawn
- Cliniques Universitaires Saint-Luc - Serv. Pédiatrie
-
Namur, Belgium, 5000
- Withdrawn
- CHU - UCL Namur - Site Sainte Elisabeth_Namur_1
-
-
-
-
-
Ostrava-Poruba, Czechia, 708 00
- Recruiting
- Fakultni Nemocnice Ostrava
-
Usti nad Labem, Czechia, 40011
- Recruiting
- Masarykova nemocnice v Usti nad Labem, o.z. - Detska klinika
-
-
-
-
-
Athens, Greece, GR-11526
- Recruiting
- Henry Dunant Hospital Center,2nd Internal Medicine Clinic
-
Athens, Greece, GR-15125
- Recruiting
- Athens Paediatric Center
-
Athens, Greece, GR-15125
- Recruiting
- Iatriko Athinon (Athens Medical Canter)
-
Haidari-Athens, Greece, GR-12462
- Recruiting
- U.G.H. "Attikon", Pediatric Endocrinology Outpatient Clinic
-
Haidari-Athens, Greece, GR-12462
- Recruiting
- University Hospital of Athens ATTIKON
-
Ioannina, Greece, 45500
- Recruiting
- University General Hospital of Ioannina, Endocrinology
-
Lamia, Greece, GR35100
- Recruiting
- General Hospital of Lamia
-
Larissa, Greece, GR-41110
- Recruiting
- Univ Gen Hospital Larisa, Endocrinology & Metabolic Disease
-
Penteli, Athens, Greece, 15236
- Not yet recruiting
- Pentelis Children's Hospital
-
Thessaloniki, Greece, GR-54636
- Recruiting
- "AHEPA" University General Hospital of Thessaloniki
-
Thessaloniki, Greece, GR-54643
- Recruiting
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
-
-
-
-
Thriruvananthapuram, India, 695 032
- Recruiting
- Jothydev's Diabetes & Research Center
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, India, 522001
- Recruiting
- Endolife Specialty Hospitals
-
-
Maharashtra
-
Kolhapur, Maharashtra, India, 416008
- Recruiting
- Excel Endocrine Centre
-
Mumbai, Maharashtra, India, 4000016
- Recruiting
- P D Hinduja National Hospital and Medical Research Centre
-
-
New Delhi
-
New Dehli, New Delhi, India, 110029
- Recruiting
- All India Institute of Medical Sciences
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302017
- Recruiting
- Eternal Heart Care Centre
-
-
Telangana
-
Hyderabad, Telangana, India, 500072
- Recruiting
- Ramdev Rao Hospital
-
-
West Bengal
-
Kolkata, West Bengal, India, 700020
- Withdrawn
- SSKM
-
Kolkata, West Bengal, India, 700020
- Not yet recruiting
- SSKM
-
-
-
-
-
Beer Sheva, Israel, 84101
- Recruiting
- Soroka Medical Center - Pediatric Endocrinology
-
Haifa, Israel, 31096
- Recruiting
- Rambam Medical Center Children A Dept.
-
-
-
-
-
Hazmieh, Lebanon, 21211
- Recruiting
- Chronic Care Center
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Recruiting
- University Malaya Medical Centre
-
Putrajaya, Malaysia, 62250
- Recruiting
- Hospital Putrajaya
-
-
Wilayah Persekutuan Kuala Lumpur
-
Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia, 59100
- Recruiting
- University Malaya Medical Centre
-
-
-
-
-
Puebla, Mexico, 72190
- Recruiting
- Consultorio de Endocrinología y Pediatría
-
-
-
-
-
Rabat, Morocco, 10000
- Recruiting
- Hôpital D'Enfants
-
-
-
-
-
Almere, Netherlands, 1315 RC
- Suspended
- De KinderKliniek
-
Den Bosch, Netherlands, 5223 GZ
- Recruiting
- Jeroen Bosch Ziekenhuis
-
-
-
-
-
Grafton, New Zealand, 1023
- Recruiting
- Liggins Institute
-
-
-
-
-
Skopje, North Macedonia, 1000
- Recruiting
- PHI University Clinic for Children's Diseases-Skopje
-
-
-
-
-
Lisboa, Portugal, 1500-650
- Recruiting
- Hospital da Luz
-
Lisboa, Portugal, 1649-035
- Active, not recruiting
- Centro Hospitalar Lisboa Norte
-
Vila Nova de Gaia, Portugal, 4400-129
- Recruiting
- Centro Hospitalar de Vila Nova de Gaia
-
-
-
-
-
Ponce, Puerto Rico, 00716
- Recruiting
- Ponce Med School Found Inc
-
-
-
-
-
Brasov, Romania, 500260
- Recruiting
- Diabet Center SRL
-
Bucharest, Romania, 041451
- Recruiting
- Spitalul Clinic de Urgenta pentru Copii "M.S.Curie"
-
Constanta, Romania, 900591
- Recruiting
- Emergency County Hospital Constanta
-
-
Dambovita
-
Targoviste, Dambovita, Romania, 130083
- Recruiting
- Spitalul Judetean de Urgenta Targoviste
-
-
-
-
-
Ekaterinburg, Russian Federation, 620149
- Withdrawn
- SAHI Sverdlovsk Reg "Regional Children's Clinical Hospital"
-
Izhevsk, Russian Federation, 426009
- Withdrawn
- Republic Children's Hospital of Ministry of Health of Udmurt
-
Moscow, Russian Federation, 125373
- Withdrawn
- RMAPE
-
Novosibirsk, Russian Federation, 630048
- Withdrawn
- NSMU paediatric clinic
-
Omsk, Russian Federation, 644001
- Completed
- GFHI Omsk Region "Regional Children's Clinical Hospital"
-
Saint-Petersburg, Russian Federation, 191144
- Withdrawn
- SPSBHI City Children out-patient clinic #44
-
Tomsk, Russian Federation, 634050
- Completed
- Siberian State Medical University
-
-
-
-
-
Taipei, Taiwan, 104
- Recruiting
- Mackay Memorial Hospital- Taipei
-
Taoyuan, Taiwan, 333
- Recruiting
- Department of Pediatrics, Chang Gung Memorial Hospital-LinKo
-
-
-
-
-
Dnipro, Ukraine, 49023
- Recruiting
- CNPE "City Clinical Hospital #9 Dnipro City Council"
-
Kharkiv, Ukraine, 61000
- Recruiting
- Kharkiv Regional Children Clincial Hospital_Lubyanka
-
Kiev, Ukraine, 01021
- Withdrawn
- Scientific and Practical Center of Endocrine Surgery
-
Kyiv, Ukraine, 03039
- Completed
- "Verum clinic" LLC
-
Kyiv, Ukraine, 04114
- Withdrawn
- Institute of Endocrinology and Metabolism of AMSU
-
Vinnytsia, Ukraine, 21010
- Withdrawn
- Vinnytsia Med University based on RegionalEndocrinDispensary
-
-
-
-
-
Birmingham, United Kingdom, B4 6NH
- Recruiting
- Birmingham Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Withdrawn
- UAB Ped Endo Children's Hosp
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hosp-Los Angeles
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Withdrawn
- Yale School of Medicine
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Recruiting
- Nemours Chld Clnc Jacksonville
-
Tampa, Florida, United States, 33612
- Recruiting
- University of South Florida Diabetes Center
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Recruiting
- Columbus Research Foundation
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana Uni School of Med-Ped
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- University Of Louisville Research Foundation
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808-4124
- Withdrawn
- Pennington Biomed Research Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21229
- Recruiting
- Barry J. Reiner, MD LLC
-
Baltimore, Maryland, United States, 21229
- Withdrawn
- Barry J. Reiner, MD LLC
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- Suspended
- University of Mississippi Medical Center
-
-
New York
-
Buffalo, New York, United States, 14203
- Recruiting
- UBMD Peds-Div of Endo/Diabetes
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- UPMC Child Hosp-Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Withdrawn
- Monument Health Clinical Rsrch
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University Medical Center
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Recruiting
- Texas Tech University HSC
-
San Antonio, Texas, United States, 78207
- Recruiting
- Univ Of Texas Hlth Science Cntr
-
San Antonio, Texas, United States, 78233
- Recruiting
- NE Clin Res of San Antonio
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Virginia Commonwealth University_Richmond
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Informed consent from parent(s) or legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- Male or female, aged 10 to below 18 years at the day of randomisation
- HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive)
- Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association criteria and treated with:
- stable metformin dose (stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 56 days or longer prior to screening) or
- stable metformin dose and a stable dose of basal insulin (stable dose of basal insulin is defined as basal insulin treatment equal to or more than 30 days prior to screening, compared to the dose at screening, dose adjustments of ± 25% are allowed) or
- stable dose of basal insulin
Exclusion Criteria:
- Diagnosis of type 1 diabetes
- Maturity onset diabetes of the young (MODY)
- Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Semaglutide - max. tolerated dose
Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
|
Oral semaglutide treatment for 52 weeks.
All participants will be dose-escalated to an individual maximum tolerated dose.
|
Placebo Comparator: Placebo (semaglutide)
Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
|
Placebo treatment for 52 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in glycosylated haemoglobin (HbA1c)
Time Frame: Week 0, week 26
|
Percentage point
|
Week 0, week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in fasting plasma glucose (FPG)
Time Frame: Week 0, week 26
|
mmol/L
|
Week 0, week 26
|
Change from baseline in body mass index (BMI) standard deviation score (SDS)
Time Frame: Week 0, week 26
|
SDS
|
Week 0, week 26
|
Change from baseline in glycosylated haemoglobin (HbA1c)
Time Frame: Week 0, week 52
|
Percentage point
|
Week 0, week 52
|
Change from baseline in FPG
Time Frame: Week 0, week 52
|
mmol/L
|
Week 0, week 52
|
Change from baseline in body weight
Time Frame: Week 0, week 26
|
kg
|
Week 0, week 26
|
Change from baseline in body weight
Time Frame: Week 0, week 52
|
kg
|
Week 0, week 52
|
Relative change from baseline in body weight
Time Frame: Week 0, week 26
|
Percentage
|
Week 0, week 26
|
Relative change from baseline in body weight
Time Frame: Week 0, week 52
|
Percentage
|
Week 0, week 52
|
Change from baseline in waist circumference
Time Frame: Week 0, week 26
|
cm
|
Week 0, week 26
|
Change from baseline in waist circumference
Time Frame: Week 0, week 52
|
cm
|
Week 0, week 52
|
Change from baseline in BMI SDS
Time Frame: Week 0, week 52
|
SDS
|
Week 0, week 52
|
BMI percentile (age and gender adjusted)
Time Frame: Week 0, week 26
|
Percent
|
Week 0, week 26
|
BMI percentile (age and gender adjusted)
Time Frame: Week 0, week 52
|
Percent
|
Week 0, week 52
|
Change from baseline in systolic blood pressure
Time Frame: Week 0, week 26
|
mmHg
|
Week 0, week 26
|
Change from baseline in systolic blood pressure
Time Frame: Week 0, week 52
|
mmHg
|
Week 0, week 52
|
Change from baseline in diastolic blood pressure
Time Frame: Week 0, week 26
|
mmHg
|
Week 0, week 26
|
Change from baseline in diastolic blood pressure
Time Frame: Week 0, week 52
|
mmHg
|
Week 0, week 52
|
HbA1c below 7.0% (53 mmol/mol) (yes/no), American Diabetes Association (ADA) target and International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines from 2018
Time Frame: At week 26
|
Count of participants
|
At week 26
|
HbA1c equal to or below 6.5% (48 mmol/mol) (yes/no), American Association of Clinical Endocrinologists (AACE) target
Time Frame: At week 26
|
Count of participants
|
At week 26
|
HbA1c below 7.0% (53 mmol/mol) (yes/no), ADA target and ISPAD guidelines from 2018
Time Frame: At week 52
|
Count of participants
|
At week 52
|
HbA1c equal to or below 6.5% (48 mmol/mol) (yes/no), AACE targetat week 26
Time Frame: At week 52
|
Count of participants
|
At week 52
|
Time to additional anti-diabetic medication (to support the treatment policy estimand)
Time Frame: Week 0 - week 52
|
Days
|
Week 0 - week 52
|
Time to rescue medication (to support the hypothetical estimand)
Time Frame: Week 0 - week 52
|
Days
|
Week 0 - week 52
|
Number of treatment-emergent adverse events (TEAEs) during exposure to trial product
Time Frame: Week 0 - week 57
|
Count of events
|
Week 0 - week 57
|
Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes
Time Frame: From randomisation (week 0) to week 26
|
Count of episodes
|
From randomisation (week 0) to week 26
|
Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes during exposure to trial product
Time Frame: Week 0 - week 57
|
Count of episodes
|
Week 0 - week 57
|
Treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemia episode
Time Frame: From randomisation (week 0) to week 26
|
Count of participants
|
From randomisation (week 0) to week 26
|
Treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemia episode during exposure to trial product
Time Frame: Week 0 - week 57
|
Count of participants
|
Week 0 - week 57
|
Change from baseline in amylase
Time Frame: Week 0, week 26
|
U/L
|
Week 0, week 26
|
Change from baseline in amylase
Time Frame: Week 0, week 52
|
U/L
|
Week 0, week 52
|
Change from baseline in lipase
Time Frame: Week 0, week 26
|
U/L
|
Week 0, week 26
|
Change from baseline in lipase
Time Frame: Week 0, week 52
|
U/L
|
Week 0, week 52
|
Change from baseline in insulin-like growth factor 1 (IGF-1)
Time Frame: Week 0, week 26
|
ng/mL
|
Week 0, week 26
|
Change from baseline in insulin-like growth factor 1 (IGF-1)
Time Frame: Week 0, week 52
|
ng/mL
|
Week 0, week 52
|
Change from baseline in insulin-like growth factor binding protein 3 (IGFBP 3)
Time Frame: Week 0, week 26
|
ng/mL
|
Week 0, week 26
|
Change from baseline in insulin-like growth factor binding protein 3 (IGFBP 3)
Time Frame: Week 0, week 52
|
ng/mL
|
Week 0, week 52
|
Change from baseline in calcitonin
Time Frame: Week 0, week 26
|
pmol/L
|
Week 0, week 26
|
Change from baseline in calcitonin
Time Frame: Week 0, week 52
|
pmol/L
|
Week 0, week 52
|
Change from baseline in estradiol (for girls)
Time Frame: Week 0, week 26
|
pmol/L
|
Week 0, week 26
|
Change from baseline in estradiol (for girls)
Time Frame: Week 0, week 52
|
pmol/L
|
Week 0, week 52
|
Change from baseline in testosterone (for boys)
Time Frame: Week 0, week 26
|
nmol/L
|
Week 0, week 26
|
Change from baseline in testosterone (for boys)
Time Frame: Week 0, week 52
|
nmol/L
|
Week 0, week 52
|
Change from baseline in prolactin
Time Frame: Week 0, week 26
|
mIU/L
|
Week 0, week 26
|
Change from baseline in prolactin
Time Frame: Week 0, week 52
|
mIU/L
|
Week 0, week 52
|
Change from baseline in thyroid stimulating hormone (TSH/thyrotropin)
Time Frame: Week 0, week 26
|
mIU/L
|
Week 0, week 26
|
Change from baseline in thyroid stimulating hormone (TSH/thyrotropin)
Time Frame: Week 0, week 52
|
mIU/L
|
Week 0, week 52
|
Change from baseline in follicle stimulating hormone (FSH)
Time Frame: Week 0, week 26
|
mIU/mL
|
Week 0, week 26
|
Change from baseline in follicle stimulating hormone (FSH)
Time Frame: Week 0, week 52
|
mIU/mL
|
Week 0, week 52
|
Change from baseline in luteinizing hormone (LH)
Time Frame: Week 0, week 26
|
mIU/mL
|
Week 0, week 26
|
Change from baseline in luteinizing hormone (LH)
Time Frame: Week 0, week 52
|
mIU/mL
|
Week 0, week 52
|
Change from baseline in dehydroepiandrosterone sulfate (DHEAS)
Time Frame: Week 0, week 26
|
μmol/L
|
Week 0, week 26
|
Change from baseline in dehydroepiandrosterone sulfate (DHEAS)
Time Frame: Week 0, week 52
|
μmol/L
|
Week 0, week 52
|
Anti-semaglutide antibodies cross reacting with endogenous GLP-1
Time Frame: Week 0 to week 57
|
Count of participants
|
Week 0 to week 57
|
Cross reacting antibodies with in vitro neutralising effect to endogenous GLP-1
Time Frame: Week 0 to week 57
|
Count of participants
|
Week 0 to week 57
|
Height velocity
Time Frame: At week 26
|
cm/year
|
At week 26
|
Height velocity
Time Frame: At week 52
|
cm/year
|
At week 52
|
Change from baseline in height SDS
Time Frame: Week 0, week 26
|
SDS
|
Week 0, week 26
|
Change from baseline in bone age assessment, X-ray
Time Frame: Week 0, week 52
|
Years
|
Week 0, week 52
|
Change from baseline in pubertal assessment (Tanner staging)
Time Frame: Week 0, week 26
|
Stage 1-5 where 5 is full sexual maturity
|
Week 0, week 26
|
Change from baseline in pubertal assessment (Tanner staging)
Time Frame: Week 0, week 52
|
Stage 1-5 where 5 is full sexual maturity
|
Week 0, week 52
|
Change from baseline in pulse rate
Time Frame: Week 0, week 26
|
Beats/minute
|
Week 0, week 26
|
Change from baseline in pulse rate
Time Frame: Week 0, week 52
|
Beats/minute
|
Week 0, week 52
|
Change from pre-dose to post-dose (25 and 40 min) in lactate
Time Frame: At week 12
|
mmol/L
|
At week 12
|
Change from pre-dose to post-dose (25 and 40 min) in lactate
Time Frame: At week 26
|
mmol/L
|
At week 26
|
Apparent clearance (CL/F)
Time Frame: Week 0 - week 52
|
L/h
|
Week 0 - week 52
|
Average concentration (Cavg)
Time Frame: Week 0 - week 52
|
nmol/L
|
Week 0 - week 52
|
Anti-semaglutide antibody status
Time Frame: Week 0 - week 57
|
Count of participants
|
Week 0 - week 57
|
Anti-semaglutide antibody titer
Time Frame: Up to 57 weeks
|
Count of participants
|
Up to 57 weeks
|
Anti-semaglutide antibodies with in vitro neutralising effect to semaglutide
Time Frame: Week 0 to week 57
|
Count of participants
|
Week 0 to week 57
|
SNAC plasma concentrations
Time Frame: Week 0 - week 52
|
ng/mL
|
Week 0 - week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Reporting Anchor and Disclosure (1452), Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2020
Primary Completion (Estimated)
February 17, 2025
Study Completion (Estimated)
March 17, 2026
Study Registration Dates
First Submitted
October 16, 2020
First Submitted That Met QC Criteria
October 16, 2020
First Posted (Actual)
October 22, 2020
Study Record Updates
Last Update Posted (Actual)
March 20, 2024
Last Update Submitted That Met QC Criteria
March 19, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9924-4437
- U1111-1218-1527 (Other Identifier: World Health Organization (WHO))
- 2018-002952-34 (Registry Identifier: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Oral semaglutide
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SEnrolling by invitation
-
Novo Nordisk A/SCompletedHealthy Volunteers Type 2 DiabetesUnited Kingdom
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersGermany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SWithdrawn